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ABSTRACT
Integrins αvβ3 and αvβ5 regulate angiogenesis and invasiveness in cancer, 
potentially by modulating activation of the transforming growth factor (TGF)-β 
pathway. The randomized phase III CENTRIC and phase II CORE trials explored 
the integrin inhibitor cilengitide in patients with newly diagnosed glioblastoma 
with versus without O6-methylguanine DNA methyltransferase (MGMT) promoter 
methylation. These trials failed to meet their primary endpoints.
Immunohistochemistry was used to assess the levels of the target integrins 
of cilengitide, αvβ3 and αvβ5 integrins, of αvβ8 and of their putative target, 
phosphorylation of SMAD2, in tumor tissues from CENTRIC (n=274) and CORE 
(n=224).
αvβ3 and αvβ5 expression correlated well in tumor and endothelial cells, but showed 
little association with αvβ8 or pSMAD2 levels. In CENTRIC, there was no interaction 
between the biomarkers and treatment for prediction of outcome. In CORE, higher 
αvβ3 levels in tumor cells were associated with improved progression-free survival by 
central review and with improved overall survival in patients treated with cilengitide.
Integrins αvβ3, αvβ5 and αvβ8 are differentially expressed in glioblastoma. 
Integrin levels do not correlate with the activation level of the canonical TGF-β 
pathway. αvβ3 integrin expression may predict benefit from integrin inhibition in 
patients with glioblastoma lacking MGMT promoter methylation.
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INTRODUCTION
Integrins are a family of 24 heterodimeric cell 
surface receptors that participate in signal transduction 
during many cellular processes. They are also involved 
in cellular communication with the extracellular matrix, 
e.g. during adhesion, motility, migration, invasion and 
angiogenesis. Their abundant expression in tumor-
associated endothelial cells [1, 2] and presumed biological 
roles led to integrins αvβ3 and αvβ5 being identified 
and validated as therapeutic targets in glioblastoma 
in preclinical models [3, 4]. These data supported the 
clinical development program for the pentapeptide, first-
in-class integrin inhibitor, cilengitide [5, 6]. In phase I, 
dose-limiting toxicity was not seen at doses up to 2400 
mg/m2, whereas clinical activity was seen at both low and 
high levels [7]. A randomized phase II trial in recurrent 
glioblastoma comparing two different doses of cilengitide 
noted a moderate radiological response rate, interpreted 
to reflect biological activity, and a trend towards 
better outcome with the higher dose of cilengitide [8]. 
Improved outcome at higher dose was also observed in a 
randomized phase II trial in the newly diagnosed setting 
in combination with the standard of care, temozolomide 
chemoradiotherapy (TMZ/RT→TMZ) [9]. An earlier 
uncontrolled phase II trial indicated preferential benefit 
from cilengitide in newly diagnosed glioblastoma patients 
with, as opposed to without, O6-methylguanine DNA 
methyltransferase (MGMT) promoter methylation [10].
Based on these data, separate trials were designed 
for patients with (“CENTRIC”) and without (“CORE”) 
MGMT promoter methylation. The phase III CENTRIC 
trial was designed to verify the activity of cilengitide 
in newly diagnosed patients with MGMT promoter 
methylation. The exploratory phase II CORE trial 
explored, in addition, whether intensified the dose of 
cilengitide during radiotherapy might provide a signal of 
activity in patients with tumors lacking MGMT promoter 
methylation, too. Neither trial demonstrated biological 
activity of cilengitide defined by the primary endpoints of 
the trials [11, 12], resulting in the discontinuation of the 
clinical development of cilengitide.
Detailed analysis of the expression of the target 
integrins of cilengitide, αvβ3 and αvβ5 in tumor and 
endothelial cells, might result in a better understanding 
of these disappointing trial results. Unfortunately, tumor 
tissues were not systematically collected in the earlier 
trials, and appropriate antibodies have only recently been 
generated [13].
While αvβ3 and αvβ5 expression in glioblastoma 
have been related mainly to angiogenesis, αvβ8 has 
been attributed roles in migration and invasion [14-
16]. Among the multiple effects of integrin signaling, 
we have recently delineated how the target integrins of 
cilengitide, αvβ3 and αvβ5, as well as αvβ8 integrin, 
may control activity of the transforming growth 
factor (TGF)-β pathway [17-19], which has been 
linked to the malignant phenotype of glioblastoma. 
Specifically, we observed that either exposure to 
cilengitide or gene silencing of αvβ3, αvβ5 or αvβ8, 
or neutralizing antibodies to these integrins reduced 
(TGF)-β1/2 mRNA expression, protein release and 
pSMAD2 phosphorylation, a surrogate marker of 
canonical TGF-β pathway activation [20], in glioma 
cells [17]. Conversely, integrin αvβ3 expression had 
previously been reported to be induced by TGF-β 
[21], potentially constituting a positive feedback loop. 
These data indicated that pSmad2 levels could serve as 
a biomarker to identify integrin signaling-dependent 
tumors. While the prognostic role of elevated pSMAD2 
levels has remained controversial [20, 22], TGF-β itself 
is also a candidate therapeutic target in glioblastoma 
[23]. Accordingly, here we studied integrin expression 
profiles in tumors of patients enrolled in the CENTRIC 
and CORE trials and explored whether these expression 
profiles were related to levels of pSMAD2 and outcome.
RESULTS
Tumor and patient characteristics
We studied the levels of integrins αvβ3, αvβ5 and αvβ8 
and of pSMAD2 by immunocytochemistry in tissues obtained 
at study entry from patients randomized into the CENTRIC 
or CORE trials. Tissue samples from 498 patients were 
analyzed, representing 61% of the patient cohorts. For 39% 
of the patients, no or insufficient tumor tissue was submitted 
or available for ancillary biological investigations. Samples 
were received from 106 and 52 centers in CENTRIC and 
CORE, respectively, whereof 35 centers were in common. 
Patient characteristics, treatment received and outcome by 
trial and in the biomarker cohort are summarized in Table 1. 
Patients in all groups received a median of 6 cycles of TMZ. 
That PFS in CORE is still only 6 months from randomization, 
can be explained by the recommendation to consider the 
possibility of pseudoprogression in the adjuvant treatment 
phase and not to stop adjuvant TMZ too early unless there 
was unequivocal PD. There was no significant outcome 
difference between the patients in the biomarker cohort and 
those where biomarkers were not evaluated (Supplementary 
Table S1).
Integrin and pSMAD2 staining patterns
The expression of the integrins within most tumor 
samples was heterogeneous. Staining was localized to 
the cytoplasm with sparing of the nuclei and without 
membranous accentuation. Representative staining patterns 
illustrating the H scores are depicted in Figure 1. Antigen 
expression was evaluated separately in the tumor and 
endothelial compartments. The quantitative assessments 
are summarized in Table 2 and Figure 2. In CENTRIC, 
Oncotarget15020www.impactjournals.com/oncotarget
Table 1: Summary of patient characteristics, treatment delivery and outcome
CENTRIC
All
Patients
N=545
CENTRIC
Biomarker Cohort
n=274
CORE
All
Patients
N=265
CORE
Biomarker Cohort
n=224
Age at baseline
  Median (years) 57.9 58.8 56.2 56.6
  Range (years) 21.7 - 81.0 21.7-81.0 20.8 - 77.5 20.8 - 76.5 
Gender
  Male 291 (53.4) 148 (54.0%) 155 (58.5) 131 (58.5)
  Female 254 (46.6) 126(46.0%) 110 (41.5) 93 (41.5)
Histological subtype
    Glioblastoma 496 (91.0) 248 (90.5) 251 (94.7) 211 (94.2)
    Gliosarcoma 21 (3.9) 10 (3.6) 10 (3.8) 9 (4.0) 
    Giant cell 17 (3.1) 12 (4.4) 3 (1.1) 3 (1.3)
    Other 11 (2.0) 4 (1.5) 1 (0.4) 1 (0.4)
ECOG Performance 
Status at baseline
  PS 0 309 (56.7) 163 (59.5) 131 (49.4) 111 (49.6)
  PS 1 236 (43.3) 111 (40.5) 132 (49.8) 111 (49.6)
No data 0 (0.0) 0 (0.0) 2 (0.8) 2 (0.9)
Surgery
Subtotal resection 
(partial/biopsy)
274 (50.3) 128 (46.7) 128 (48.3) 102 (45.5) 
Gross total resection 269 (49.4) 144 (52.6) 136 (51.3) 121 (54.0)
No data 2 (0.4) 2 (0.7) 1 (0.4) 1 (0.4)
Treatment received
TMZ (n=273) TMZ (n=137) TMZ (n=89) TMZ (n=71)
Received study 
intervention 258 (94.5) 130 (94.9) 85(95.5) 68 (95.8)
Started RTX 256 (93.8) 129 (94.2) 85(95.5) 68 (95.8)
Started maintenance 
TMZ 211 (77.3) 106 (77.4) 71(80.0) 58 (81.7)
Number of TMZ 
maintenance cycles
Median 6 6 6 6
Range 1-32 1-21 1-11 1-8
Cilengitide (n=272) Cilengitide (n=137) Cilengitide (n=176) Cilengitide (n=153)
Received study 
intervention 263 (96.7) 133 (97.0) 170(96.6) 147(96.1)
Started Pre-RTX phase 259 (95.2) 131 (95.6) 168(95.5) 146(95.4)
Started RTX phase 260 (95.6) 131 (95.6) 168(95.5) 146(95.4)
Started maintenance 
TMZ 221 (81.3) 111 (81.0) 144(81.8) 125(81.7)
Number of TMZ 
maintenance cycles
(Continued )
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CENTRIC
All
Patients
N=545
CENTRIC
Biomarker Cohort
n=274
CORE
All
Patients
N=265
CORE
Biomarker Cohort
n=224
Median 6 6 6 6
Range 1-21 1-21 1-19 1-19
Started cilengitide 
monotherapy phase 168 (61.8) 77 (56.2) 85(48.3) 74(48.4)
Total number of 
cilengitide infusions
Median 90 72 69 69
Range 1-388 1-317 2-224 2-224
Outcome
   Median PFS (months, 
95% CI)
12.3 (10.6, 13.6) 12.1 (10.4,13.6) 6.2 (5.9, 7.7) 6.3 (5.9, 7.7)
   Median OS (months, 
95% CI)
26.3 (24.4, 29.3) 25.4 (23.3,30.9) 14.4 (13.4, 15.6) 14.1 (12.9, 15.5)
Figure 1: Immunohistochemical assessment of integrins and pSmad2 in glioblastoma. Representative sections immunostained 
for αvβ3, αvβ5, αvβ8 and pSMAD2. Negative staining of tumor tissue with immunolabeled vasculature as internal positive control (left 
column), H score (tumor) < 100 second column, H score (tumor) 101-200 third column, H score (tumor) >200 (right column), size bars 
correspond to 200 μm.
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αvβ3 levels in tumor cells correlated weakly with αvβ3 
in endothelial cells (SSC=0.26, p<0.0001), with αvβ5 in 
tumor cells (SSC=0.18, p=0.002) and with αvβ5 levels in 
endothelial cells (SSC=0.16, p=0.006). αvβ5 levels in tumor 
and endothelial cells were also weakly correlated (SSC=0.17, 
p=0.003) whereas pSMAD2 levels in both compartments 
showed strong correlation (SSC=0.50, p<0.0001). In 
CORE, αvβ3 levels in tumor cells weakly correlated with 
αvβ3 levels in endothelial cells (SSC=0.26,p<0.001) and 
with αvβ5 levels in endothelial cells (SSC=0.29, p<0.001). 
αvβ5 levels in tumor and endothelial cells were weakly 
correlated (SSC=0.29, p<0.001). αvβ5 levels in endothelial 
Table 2: Quantitative assessment of immunohistochemistry data.
CENTRIC biomarker 
cohort
n=274*
CORE biomarker cohort
n=224*
αvβ3 tumor cells
Median 0 0
Range 0–220 0–300
N 294 241
αvβ3 endothelial cells
Median 10 30
Range 0-300 0-300
N 294 241
αvβ5 tumor cells
Median 60 90
Range 0-285 0-300
N 294 237
αvβ5 endothelial cells
Median 125 140
Range 0-280 0-300
N 292 236
αvβ8 tumor cells
Median 180 200
Range 0-300 0-300
N 283 231
αvβ8 endothelial cells
Median 0 0
Range 0-120 0-150
N 283 231
pSMAD2 tumor cells
Median 70 79
Range 0-270 0-260
N 281 227
pSMAD2 endothelial cells
Median 30 46
Range 0-145 0-190
N 281 227
*Note that n in the table may be higher for individual markers since the biomarker cohorts were defined as patients with 
tumors where all markers were assessed.
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Figure 2: Quantitative assessment of immunohistochemistry data. Boxplots of biomarker expression in the CENTRIC A. and 
CORE B. biomarker cohorts are depicted. The boxes represent the interquartile range split by the medians. Diamonds represent the means. 
Lines extending horizontally from the boxes indicate variability outside the range (lowest value within 1.5 IQR of Q1, and highest value 
within 1.5 IQR of Q3). Outliers beyond 1.5 IQR are plotted as individual points.
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cells correlated weakly with αvβ8 in tumor cells (SSC=0.21, 
p=0.002). There was good correlation between pSMAD2 
levels in both compartments (SSC=0.55, p<0.001) 
(Supplementary Table S2). Investigation of the relationship 
among the different markers by PCA illustrated in Figure 3A 
underlines the correlations detailed above. It does not support 
a direct relationship between the integrins and pSMAD2 
levels as measured by immunohistochemistry. The markers 
Figure 3: Principal component analysis (PCA) of biomarker analyses. A. The histoscores of the markers for tumor (HST) and 
endothelial cells (HSE) are represented on the first vectorial plan of the PCA. The two first distinct eigenvalues (Histogram of Eigenvalues, in 
black) explain 42.6% of the total variation. B. The patient samples are projected onto the two first axes of the PCA and patterns were explored 
by Kernel Density Estimation (KDE) in these two dimensions (green curves). No indications for marker driven subgroups are observed. C. 
Each patient sample is represented by a square, with proportional size to the distance to the mean age (55.3 years). The white and black squares 
identify the patients with age inferior or superior to the mean age, respectively. D. The impact of the study (CENRTIC/CORE) was investigated 
on the two first axes visualized by the inertia ellipses for CENTRIC (red) and CORE (black). A significant difference is observed (P < 0.001, 
between-group permutation tests) illustrated by a histogram, where the observed value is given by a black vertical line.
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analyzed do not segregate the tumors into different subgroups 
(Figure 3B). Further, exploration of the major sources of 
variation among tumors did not indicate any difference by 
gender (p=0.088, not shown), or age (Figure 3C, p=0.380), 
but a significant difference between the two studies, 
CENTRIC and CORE (p=0.001) was observed (Figure 3D). 
However, the analysis of the variation fraction revealed that 
the variable “center” explained 40% of the total variation 
(between-group ratio=0.403, p-value < 0.001), and only 2% 
were attributed to differences between the studies (between-
group ratio=0.022, p-value< 0.001). Nevertheless, the overall 
structure of the relationships among markers between CORE 
and CENTRIC, when analyzed separately, is preserved (not 
shown).
Clinical pathological correlations
In the CENTRIC cohort, there was no significant 
interaction between the biomarkers and treatment for the 
prediction of PFS determined by central review (Figure 4A) 
Figure 4: Forest plots: predictive value of biomarkers for the efficacy of cilengitide for PFS assessed by central review. 
A. CENTRIC. (Continued ) 
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Figure 4: (Continued ) Forest plots: predictive value of biomarkers for the efficacy of cilengitide for PFS assessed by 
central review. B. CORE. On the left-hand, the integrin subgroups with numbers of events/sample size by treatment arm, number of 
missing data, and hazard ratios (HR) with 95% confidence intervals are shown. The vertical line represents the absence of differential 
effects between the two treatments, i.e., if for an integrin subgroup, the 95% confidence intervals overlap with this line, it indicates that 
treatment effects are not different. The square represents the Cilengitide/TMZ hazard ratio in the integrin subgroup. The area of each 
square is proportional to the number of events. The diamond indicates a differential effect of treatment in the whole cohort. Diamond 
overlapping the vertical lines indicates in-significantly different treatment effects at 5% significance. On the right-hand, interaction tests 
are presented. They assess the significance of a differential treatment effect between two integrin subgroups, i.e., tests have one degree 
of freedom (df=1).
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or investigator assessment (Supplementary Figure S1A) 
or for the prediction of OS (Figure 5A). In contrast, in 
CORE, higher αvβ3 levels in tumor cells were associated 
with improved PFS by central review (Figure 4B, p=0.036) 
and improved OS (Figure 5B, p=0.02) in patients treated 
with cilengitide. This effect persisted when analysed 
stratified for prognostic factors, including age, RPA score, 
extent of surgery, MMSE, or ECOG PS (data on shown). 
However, the PFS effect was not confirmed when exploring 
investigator-assessed PFS (investigator PFS interaction test 
p=0.345, IRC PFS p=0.036) (Supplementary Figure S1B).
In order to maximize the statistical power, the 
univariate prognostic value of the biomarkers was assessed 
in the whole cohort. No significant association of integrin 
expression in tumor or endothelial cells with outcome was 
revealed in either trial cohort. Similarly, no prognostic 
role for pSMAD2 levels became apparent (Supplementary 
Table S3 and S4).
Figure 5: Forest plots: predictive value of biomarkers for the efficacy of cilengitide for OS. A. CENTRIC (Continued )
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DISCUSSION
The main goal of this study was to explore whether 
the expression patterns of the putative target integrins of 
cilengitide, αvβ3 and aβ5, might shed light on the results 
of the CENTRIC and CORE clinical trials. We find that 
the target integrins are differentially expressed in tumor 
and endothelial cells within glioblastomas (Figures 1 
and 2, Table 2). In contrast to previous analyses of smaller, 
non-clinical trial cohorts, [24] integrin expression was 
neither prognostic in the CENTRIC nor in the CORE 
biomarker cohort. The differential expression of target 
integrins either in tumor or in endothelial cells was 
unrelated to outcome with cilengitide treatment in the 
CENTRIC trial. In contrast, higher αvβ3 levels in tumor 
cells were associated with improved PFS by central review 
Figure 5: (Continued ) Forest plots: predictive value of biomarkers for the efficacy of cilengitide for OS. B. CORE (for 
detailed explanations, see Figure 4).
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and with improved OS in cilengitide-treated patients in 
the CORE cohort (Figure 4B and 5B). Patient cohorts 
from both trials were analysed separately because of the 
powerful prognostic role of MGMT promoter methylation, 
the biomarker that determined patient enrolment in either 
CENTRIC or CORE.
The levels of αvβ3 and αvβ5 correlated weakly, 
both in tumor and endothelial cells, suggesting a 
common upstream regulatory pathway regulating integrin 
expression in both compartments in glioblastoma. In 
contrast, the levels of αvβ3 and αvβ5 showed almost no 
relation to the levels of αvβ8. While αvβ8 is not a target 
of cilengitide, it may be involved in the activation of 
latent TGF-β [17, 25]. Importantly, there is no surrogate 
biomarker reflecting integrin activity as opposed to mere 
expression which may be heterogeneous within a tumor 
[26], and defining a biomarker of integrin pathway 
activation may hαve been more informative, e.g., levels of 
focal adhesion kinase or other focal adhesion-associated 
proteins. Importantly, however, the present analysis 
suggests that enrichment for patients with tumors with 
high levels of target integrin expression would not hαve 
altered the negative outcome at least in the CENTRIC 
trial.
A second goal of this study was to verify whether 
the involvement of αv integrin in controlling TGF-β 
pathway activity [17] is reflected by correlated integrin 
expression and Smad2 phosphorylation, a marker for 
TGF-β pathway activity [20]. This was not confirmed 
in either trial cohort (Figure 3; Supplementary Table 
S2), suggesting that expression of integrins alone is 
not an adequate surrogate marker for integrin activity 
in situ. Alternatively, pSMAD2 levels in glioblastoma 
and the TGF-β pathway may not be controlled by αv 
integrins to a relevant extent. Interestingly, however, 
there was strong correlation between pSMAD2 levels 
in tumor and in endothelial cells, suggesting that 
both compartments are equally responsive to TGF-β 
activity in the tumor microenvironment. Thus, escape 
from the inhibitory signaling activity of TGF-β as seen 
in other cancers, e.g., colon cancer, is not required 
in glioblastoma, at least not at the level of Smad2 
canonical signaling.
In summary, the expression patterns of the integrin 
targets of cilengitide, αvβ3 and αvβ5, did not provide 
prognostic information and did not reveal glioblastoma 
patient populations that were more or less responsive to 
cilengitide in the phase III CENTRIC trial. The weak 
association with improved outcome with cilengitide in 
patients with glioblastoma lacking MGMT promoter 
methylation in the phase II CORE trial may justify patient 
enrichment based on αvβ3 expression in tumor cells in 
future trials. Yet, agents more potent than cilengitide will 
be needed to explore whether integrins are a relevant 
target in glioblastoma, and indicators of integrin pathway 
activation may be superior biomarkers over integrin 
expression levels for patient enrichment.
MATERIALS AND METHODS
Patients
We examined tumor tissues obtained at study 
entry of patients with newly diagnosed glioblastoma 
enrolled in the CENTRIC (NCT00689221) and 
CORE (NCT00813943) trials [11, 12]. Accurate 
immunohistochemical detection of antigen in tissue was 
based on procedures published by Vogetseder et al. [27] 
which analyzed integrin expression in a TMA containing 
152 cores of non-neoplastic tissue in our laboratory. 
The biomarker cohorts were defined as patients in each 
trial where all markers could be assessed. All patients 
provided written informed consent for the clinical 
investigation and correlative science reported here. The 
protocols were approved by the local ethics committees 
or institutional review boards, and appropriate regulatory 
authorities.
Immunohistochemistry
Four μm sections of tumor tissue from paraffin-
embedded blocks were deparaffinized and immunostained 
for the expression of integrin αvβ3 (clone EM22703, 5 μg 
ml−1), αvβ5 (clone EM09902, 1 μg ml−1) and αvβ8 (clone 
EM13309, 1.3 μg ml−1) [13, 17, 27] as well as pSMAD2 
expression (Cell Signaling clone 138D4, 1:200), according 
to the Ventana protocols (Ventana Medical System). The 
semiquantitative expression level and area of staining 
on each section for αvβ3, αvβ5 and αvβ8 integrins and 
for pSMAD2 were assessed by two neuropathologists, 
independently in glioma cells and endothelial cells 
within the tumor using the semiquantitative histoscore 
(H-Score) method [28, 29]. Briefly, staining intensity is 
scored as absent (0), mild (1), moderate (2) or strong (3) 
expression. The staining intensity value is multiplied by 
the percentage of cells showing each grade of positivity, 
for a maximum total score of 300. The neuropathologists 
were blinded with regard to patient allocation to treatment 
arm and outcome. The concordance between the two 
neuropathologists was 100% since any differences in the 
initial evaluation, which were always minor, were sorted 
out until a consensus was reached. Also noteworthy is 
the fact that even though the absolute percentages of the 
various components differed somewhat among the two 
pathologists, the H-score proved to be the same.
Statistical analysis
Continuous variables (including biomarkers) were 
presented using median and range (minimum, maximum). 
Boxplots were drawn to visualize biomarker distributions. 
Frequency tables were tabulated (by whole trial and 
biomarker cohort) for all categorical variables. Spearman 
Correlation Coefficients (SCC) were computed to quantify 
the relationships between biomarkers. Correlations with 
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p values less than 1% are summarized. SSC less than 
or equal to 0.3 was considered a weak correlation. SCC 
between 0.3 and 0.49 was considered fair correlation and 
SSC equal to or above 0.5 a good correlation.
Principal component analysis (PCA) was performed 
to explore and to illustrate the correlation pattern among 
the markers. A Monte-Carlo test on between-group inertia 
(global test) based on the percentage of explained variation 
was used to test the overall difference between gender, 
centers and CENTRIC and CORE trials [30]. The PCA, 
between-group test analyses and graphic representations 
were performed using R package ade4 [31].
For progression-free survival (PFS) and overall 
survival (OS), Kaplan Meier curves were computed for 
each biomarker split by their median in each trial. Score 
tests obtained from univariate Cox regression models were 
used to assess the prognostic value of each biomarker in the 
biomarker cohort. Predictive value for treatment efficacy 
was assessed by Cox regression including treatment (TMZ/
RT→TMZ versus TMZ/RT→TMZ+Cilengitide), biomarker 
(≤ median versus > median) and treatment by biomarker 
interaction score tests. All outcome analyses were exploratory 
and performed without adjustment for multiplicity at 5% 
significance, and outcome parameters (i.e. medians, hazard 
ratios) were presented with 95% confidence intervals. In the 
CORE trial, data of both cilengitide arms pooled.
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